Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Policies)

v2.4.1.9
Significant Accounting Policies (Policies)
6 Months Ended
Jan. 31, 2015
Significant Accounting Policies  
Segment Reporting

Segment Reporting

 

The Company operates in a single industry segment — the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, intended to treat a wide range of oncology indications.

 

Concentrations and Credit Risk

Concentrations and Credit Risk

 

The Company maintains cash balances at a single financial institution and such balance commonly exceeds the $250,000 amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts and management believes that the Company does not have significant credit risk with respect to such cash and cash equivalents.

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts in the financial statements and disclosures made in the accompanying notes to the financial statements.  The Company’s significant estimates pertain to stock-based compensation expense — see Footnote 8. Actual results could differ materially from the estimates.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

Recent pronouncements that are not anticipated to have an impact on or are unrelated to the Company’s financial condition, results of operations, or related disclosures are not discussed.